KRYS · Company research
11 upcoming catalysts · 0 phase 2+ trials on file
View Stock opens Yahoo Finance. Prices and performance charts are provided there.
Krystal Biotech expects to report results from its Phase 1 study of KB407 (inhaled HSV-1 gene therapy) for Cystic fibrosis in the second half of 2026 (no exact date yet). Phase 1 is an early safety study in a small group of people.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Krystal Biotech expects to report results from its Phase 1 study of KB707 (intratumoral) for Gorlin syndrome (basal cell carcinomas) in the second half of 2026 (no exact date yet). Phase 1 is an early safety study in a small group of people.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
KB707 inhaled KYANITE-1 final dose-expansion cohort enrollment completion, expected in the second half of 2026 (no exact date yet). A company milestone for Krystal Biotech (KB707 (inhaled) for advanced NSCLC): a step in the program rather than a decision or a data readout.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
VYJUVEK additional MAA filings incl. Switzerland and Australia in 2H 2026, expected in the second half of 2026 (no exact date yet). A company milestone for Krystal Biotech (VYJUVEK (beremagene geperpavec) for dystrophic epidermolysis bullosa): a step in the program rather than a decision or a data readout.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Krystal Biotech expects to report results from its Phase 1 study of KB111 for Hailey-Hailey disease in Q4 2026 (Oct–Dec) (no exact date yet). Phase 1 is an early safety study in a small group of people.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Krystal Biotech expects to report results from its Registrational (IOLITE) study of KB803 (gene therapy eye drop) for Corneal abrasions in dystrophic epidermolysis bullosa in Q4 2026 (Oct–Dec) (no exact date yet). Registrational (IOLITE) is a study designed to support approval.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Krystal Biotech expects to report results from its Phase 1/2 study of KB407 for cystic fibrosis in Q4 2026 (Oct–Dec) (no exact date yet). Phase 1/2 is an early study that checks safety and takes a first look at effect.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
KB407 FDA alignment on CF registrational study design expected 4Q 2026, expected in Q4 2026 (Oct–Dec) (no exact date yet). A company milestone for Krystal Biotech (KB407 for cystic fibrosis): a step in the program rather than a decision or a data readout.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
KB801 EMERALD-1 neurotrophic keratitis enrollment (~60 pts) completion before year-end, expected in Q4 2026 (Oct–Dec) (no exact date yet). A company milestone for Krystal Biotech (KB801 for neurotrophic keratitis): a step in the program rather than a decision or a data readout.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Krystal Biotech expects to report results from its Phase 1/2 study of KB707 (inhaled IL-12/IL-2 immunotherapy) for Non-small cell lung cancer in the first half of 2027 (no exact date yet). Phase 1/2 is an early study that checks safety and takes a first look at effect.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Krystal Biotech expects to report results from its Phase 1 study of KB408 for alpha-1 antitrypsin deficiency during 2027 (no exact date yet). Phase 1 is an early safety study in a small group of people.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
UK regulators approved Krystal Biotech’s VYJUVEK (beremagene geperpavec-svdt) for Dystrophic epidermolysis bullosa on May 18, 2026. The company can now sell it in that market.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Krystal Biotech presented data on KB407, KB409/KB410, KB707 for Cystic fibrosis, primary ciliary dyskinesia, solid tumors at a medical meeting on Apr 30, 2026. The linked source has the details.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA approved Krystal Biotech’s Vyjuvek (B-VEC) for DEB on May 19, 2023. The company can now sell it in that market.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Explore reported politician transactions and public investor statements connected to KRYS.
View source-linked activity ↗No phase 2+ trials cached for this company.
No recent headlines on file.